<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37317638</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS.</ArticleTitle><Pagination><StartPage>e12919</StartPage><MedlinePgn>e12919</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12919</ELocationID><Abstract><AbstractText Label="AIMS">Although the orally available brain-penetrant copper compound CuATSM has demonstrated promising effects in SOD1-linked mouse models, the impact of CuATSM on disease pathology in patients with amyotrophic lateral sclerosis (ALS) remains unknown.</AbstractText><AbstractText Label="METHODS">The present study set out to address this deficit by performing the first pilot comparative analysis of ALS pathology in patients that had been administered CuATSM and riluzole [N&#x2009;=&#x2009;6 cases composed of ALS-TDP (n&#x2009;=&#x2009;5) and ALS-SOD1 (n&#x2009;=&#x2009;1)] versus riluzole only [N&#x2009;=&#x2009;6 cases composed of ALS-TDP (n&#x2009;=&#x2009;4) and ALS-SOD1 (n&#x2009;=&#x2009;2)].</AbstractText><AbstractText Label="RESULTS">Our results revealed no significant difference in neuron density or TDP-43 burden in the motor cortex and spinal cord of patients that had received CuATSM compared with patients that had not. In patients that had received CuATSM, p62-immunoreactive astrocytes were observed in the motor cortex and reduced Iba1 density was found in the spinal cord. However, no significant difference in measures of astrocytic activity and SOD1 immunoreactivity was found with CuATSM treatment.</AbstractText><AbstractText Label="DISCUSSION">These findings, in this first postmortem investigation of patients with ALS in CuATSM trials, demonstrate that in contrast to that seen in preclinical models of disease, CuATSM does not significantly alleviate neuronal pathology or astrogliosis in patients with ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Macquarie University Centre for Motor Neuron Disease Research, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-0399-3218</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kril</LastName><ForeName>Jillian J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9407-8674</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-0422-8398</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Rachel H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0002-0385-4090</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000720849">CuATSM</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43 pathology</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">copper ATSM (CuATSM)</Keyword><Keyword MajorTopicYN="N">p62 pathology</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>3</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37317638</ArticleId><ArticleId IdType="doi">10.1111/nan.12919</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104-118. doi:10.1038/s41582-020-00434-z</Citation></Reference><Reference><Citation>Hilton JB, Mercer SW, Lim NKH, et al. Cu (II)(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep. 2017;7(1):42292. doi:10.1038/srep42292</Citation></Reference><Reference><Citation>McAllum EJ, Lim NKH, Hickey JL, et al. Therapeutic effects of CuII (atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):586-590. doi:10.3109/21678421.2013.824000</Citation></Reference><Reference><Citation>Roberts BR, Lim NKH, McAllum EJ, et al. Oral treatment with Cu (II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2014;34(23):8021-8031. doi:10.1523/JNEUROSCI.4196-13.2014</Citation></Reference><Reference><Citation>Soon CPW, Donnelly PS, Turner BJ, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper (II) (CuII (atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286(51):44035-44044. doi:10.1074/jbc.M111.274407</Citation></Reference><Reference><Citation>Vieira FG, Hatzipetros T, Thompson K, et al. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2017;2:47-53. doi:10.1016/j.ibror.2017.03.001</Citation></Reference><Reference><Citation>Williams JR, Trias E, Beilby PR, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the copper-chaperone-for-SOD. Neurobiol Dis. 2016;89:1-9. doi:10.1016/j.nbd.2016.01.020</Citation></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol. 2017;133(2):177-196. doi:10.1007/s00401-016-1666-6</Citation></Reference><Reference><Citation>Muller K et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89(8):817-827. doi:10.1136/jnnp-2017-317611</Citation></Reference><Reference><Citation>Mazumder S, McCann H, D&#x2019;Silva S, et al. Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. Brain. 2022;146(3):e17-e19. doi:10.1093/brain/awac467</Citation></Reference><Reference><Citation>Brettschneider J, Arai K, del Tredici K, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128(3):423-437. doi:10.1007/s00401-014-1299-6</Citation></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92(1):86-95. doi:10.1136/jnnp-2020-322983</Citation></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, et al. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92(3):259-266. doi:10.1111/cge.12973</Citation></Reference><Reference><Citation>Tan RH, Shepherd CE, Kril JJ, et al. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun. 2013;1(1):33. doi:10.1186/2051-5960-1-33</Citation></Reference><Reference><Citation>Tan RH, Wong S, Kril JJ, et al. Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. Brain. 2014;137(Pt 7):2065-2076. doi:10.1093/brain/awu118</Citation></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138(Pt 10):3110-3122. doi:10.1093/brain/awv220</Citation></Reference><Reference><Citation>Trist BG, Genoud S, Roudeau S, et al. Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022;145(9):3108-3130. doi:10.1093/brain/awac165</Citation></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427-434. doi:10.1002/ana.21147</Citation></Reference><Reference><Citation>Hilton JB, White AR, Crouch PJ. Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics. 2016;8(9):1002-1011. doi:10.1039/C6MT00099A</Citation></Reference><Reference><Citation>Hilton JBW, Kysenius K, Liddell JR, et al. Disrupted copper availability in sporadic ALS: implications for CuII (atsm) as a treatment option. BioRxiv. 2020;</Citation></Reference><Reference><Citation>Farrawell NE, Yerbury MR, Plotkin SS, McAlary L, Yerbury JJ. CuATSM protects against the in vitro cytotoxicity of wild-type-like copper-zinc superoxide dismutase mutants but not mutants that disrupt metal binding. ACS Chem Nerosci. 2019;10(3):1555-1564. doi:10.1021/acschemneuro.8b00527</Citation></Reference><Reference><Citation>Dennys CN, Roussel F, Rodrigo R, et al. CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis. Glia. 2023;71(2):350-365. doi:10.1002/glia.24278</Citation></Reference><Reference><Citation>Liu WJ, Ye L, Huang WF, et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett. 2016;21(1):29. doi:10.1186/s11658-016-0031-z</Citation></Reference><Reference><Citation>Szebenyi K, Wenger LMD, Sun Y, et al. Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology. Nat Neurosci. 2021;24(11):1542-1554. doi:10.1038/s41593-021-00923-4</Citation></Reference><Reference><Citation>Brettschneider J, Toledo JB, van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e39216. doi:10.1371/journal.pone.0039216</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>